Theratechnologies News and Activities
Presence
Theratechnologies is a pharmaceutical company that develops and sells specialty medicines. Its main products support people with HIV and other complex conditions, and its customers include healthcare providers, hospitals, and patients.
Theratechnologies products and services overview:
- HIV treatments
- Specialty medicines
- Biologic therapies
- Oncology research
Revenue: ~$90 million
Employees: 180
Headquarters: Montreal, Canada
Theratechnologies is one of the...
Theratechnologies is a company listed under the stock ticker TH (CA).
Executives
View the org chart displaying its 8 main executives
Most searched biographies at Theratechnologies
- Paul Lévesque, Director, President and Chief Executive Officer
- André Dupras, Vice President, Human Resources
- Philippe Dubuc, Senior Vice President and Chief Financial Officer
Create your alert
to follow the executive moves at Theratechnologies.
Pharmaceuticals
Theratechnologies has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Theratechnologies
- Theratechnologies to Present at the Canaccord Genuity 42nd Annual Growth Conference | Theratechnologies Inc.
- Theratechnologies Trogarzo® Data at AIDS 2022 Shows Potential for Improved Treatment Regimens | Theratechnologies Inc.
- Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement | Theratechnologies Inc.
- Theratechnologies Provides Update on the Dose Escalation Portion of Fast Track Designated TH1902 First-in-Human Study in Advanced Resistant Malignancies | Theratechnologies Inc.
- Theratechnologies Reports Second Quarter and First Half Fiscal 2022 Financial Results and Provides Business Update | Theratechnologies Inc.
- Theratechnologies Announces Binding Commitment for a Non-Dilutive Term Loan of up to $100 million from Marathon Asset Management | Theratechnologies Inc.
- CQDM, the Quebec Breast Cancer Foundation and Theratechnologies fund close to $2 million for research project to validate the anti-metastatic potential of TH1902 at the Université du Québec à Montréal | Theratechnologies Inc.
- Theratechnologies to Announce Second Quarter 2022 Financial Results and Provide Business Update | Theratechnologies Inc.
- Press Releases | Theratechnologies Inc.
- Theratechnologies Announces New Head of Investor Relations | Theratechnologies Inc.
- View more press releases Close
Social media about Theratechnologies
- Theratechnologies on Wikipedia, Google News & Yahoo Finance
- Theratechnologies on LinkedIn, X (Twitter) & YouTube
